These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6777462)

  • 1. Abnormal regulation of prolactin release in idiopathic Parkinson's disease.
    Lawton NF; MacDermot J
    J Neurol Neurosurg Psychiatry; 1980 Nov; 43(11):1012-5. PubMed ID: 6777462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
    Martinez-Campos A; Giovannini P; Novelli A; Cocchi D; Caraceni T; Müller EE
    Acta Endocrinol (Copenh); 1982 Mar; 99(3):344-51. PubMed ID: 6803485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of levodopa on thyroid function and prolactin release. A study in patients with Parkinson's disease.
    Lavin PJ; Gawel MJ; Das PK; Alaghband-Zadeh J; Rose FC
    Arch Neurol; 1981 Dec; 38(12):759-60. PubMed ID: 6797388
    [No Abstract]   [Full Text] [Related]  

  • 4. Prolactin secretion in Parkinson disease.
    Eisler T; Thorner MO; MacLeod RM; Kaiser DL; Calne DB
    Neurology; 1981 Oct; 31(10):1356-9. PubMed ID: 6810204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
    Martinez-Campos A; Giovannini P; Parati E; Novelli A; Caraceni T; Müller EE
    J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
    Ruggieri S; Falaschi P; Baldassarre M; D'Urso R; De Giorgio G; Rocco A; Agnoli A
    Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy.
    Vogel HP; Ketsche R
    J Neurol; 1986 Jun; 233(3):149-52. PubMed ID: 3088217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease.
    Bell RD; Carruth A; Rosenberg RN; Boyar RM
    J Clin Endocrinol Metab; 1978 Oct; 47(4):807-11. PubMed ID: 45469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberoinfundibular dopaminergic function in Parkinson's disease.
    Franceschi M; Camerlingo M; Perego L; Bottacchi E; Truci G; Mamoli A
    Eur Neurol; 1988; 28(3):117-9. PubMed ID: 3133213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociation of thyrotropin and prolactin responsiveness to thyrotropin releasing hormone stimulation in L-dopa treated parkinsonian patients.
    Rabey JM; Vardi Y; Ravid R; Ayalon D
    Horm Res; 1981; 15(2):78-87. PubMed ID: 6799381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low CSF gamma-aminobutyric acid levels in Parkinson's Disease. Effect of levodopa and carbidopa.
    Manyam BV
    Arch Neurol; 1982 Jul; 39(7):391-2. PubMed ID: 7103767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response.
    Agnoli A; Baldassarre M; Ruggieri S; Falaschi P; Urso RD; Rocco A
    J Neural Transm; 1981; 51(1-2):123-34. PubMed ID: 7264625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypothalamic dysfunction in Parkinson's disease patients.
    Otake K; Oiso Y; Mitsuma T; Hirooka Y; Adachi K
    Acta Med Hung; 1994; 50(1-2):3-13. PubMed ID: 7638039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
    Juncos JL; Fabbrini G; Mouradian MM; Serrati C; Kask AM; Chase TN
    J Neurol Neurosurg Psychiatry; 1987 Feb; 50(2):194-8. PubMed ID: 3572434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter: Intravenous thyrotrophin-releasing hormone in Parkinson's disease.
    McCaul JA; Cassell KJ; Stern GM
    Lancet; 1974 Apr; 1(7860):735. PubMed ID: 4132453
    [No Abstract]   [Full Text] [Related]  

  • 16. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
    Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
    Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Patients with Parkinson disease: functional analysis of dopamine receptors by bromocriptine- thyrotropin-releasing hormone test].
    Díaz F; Liberman C; Chariá P
    Rev Med Chil; 1991 Mar; 119(3):252-7. PubMed ID: 1842116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa].
    Lombardo L; De la Garza R
    Arch Invest Med (Mex); 1977; 8(2):123-8. PubMed ID: 907417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined therapy of carbidopa and levodopa in Parkinson's disease].
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):201-4. PubMed ID: 4075908
    [No Abstract]   [Full Text] [Related]  

  • 20. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
    García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
    Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.